8th Jul 2022 14:19
MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Receives approval from South African Health Products Regulatory Authority for a Phase 2b dose finding study of its nanoparticle formulation CimetrA on patients diagnosed with Covid-19.
"The study aims to determine the most effective dosage concentrations of the active ingredients, as well as collecting data to further validate CimetrA's anti-inflammatory and immune-modulatory effects," firm explains. Immune-modulatory substances stimulate or suppress the immune system, which can help it fight infections.
MGC expects interim analysis results in the coming weeks.
Current stock price: 1.01 pence, up 12%
12-month change: down 52%
By Tom Budszus; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
MXC.L